Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes.

Blood
J AraiS Fujita

Abstract

Human telomerase reverse transcriptase (hTERT) is considered a potential target for cancer immunotherapy because it is preferentially expressed in malignant cells. hTERT-derived peptides carrying motifs for HLA-A24 (HLA-A*2402), the most common allele among Japanese and also frequently present in persons of European descent, were examined for their capacity to elicit antileukemia cytotoxic T lymphocytes (CTLs). Two of the 5 peptides tested, VYAETKHFL and VYGFVRACL, appeared capable of generating hTERT peptide-specific and HLA-A24-restricted CTLs. The CD8(+) CTL clones specific for these hTERT peptides exerted cytotoxicity against leukemia cells in an HLA-A24-restricted manner. This cytotoxicity was inhibited by the addition of hTERT peptide-loaded autologous cells, suggesting that hTERT is naturally processed in leukemia cells and that hTERT-derived peptides are expressed on these cells and are recognized by CTLs in the context of HLA-A24. Taken together with the currently identified HLA-A2-restricted CTL epitopes derived from hTERT, identification of new CTL epitopes presented by HLA-A24 increases the feasibility of immunotherapy for leukemia using hTERT-derived peptides.

References

Sep 1, 1995·Science·J FengJ Yu
Jan 1, 1995·Immunogenetics·H G RammenseeS Stevanoviíc
Feb 14, 1997·Science·L HarringtonM O Robinson
Apr 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J W Shay, S Bacchetti
Nov 22, 1997·Current Opinion in Immunology·B J Van den Eynde, P van der Bruggen
May 29, 1998·The Journal of Clinical Investigation·P YotndaP Langlade-Demoyen
Jul 17, 1998·The Journal of Clinical Investigation·P YotndaP Langlade-Demoyen
Apr 12, 2000·Proceedings of the National Academy of Sciences of the United States of America·B MinevM Zanetti

❮ Previous
Next ❯

Citations

Jul 19, 2002·International Journal of Cancer. Journal International Du Cancer·Masashi GotohTakashi Yamaoka
Jul 5, 2003·International Journal of Hematology·Yutaka Kawakami
Feb 24, 2005·Cancer Immunology, Immunotherapy : CII·Marco W J SchreursErik Hooijberg
Jan 1, 2005·Cancer Immunology, Immunotherapy : CII·Tobias KrügerStefan Stevanović
Feb 24, 2006·Cancer Immunology, Immunotherapy : CII·Paal F BrunsvigGustav Gaudernack
Apr 28, 2007·Cancer Immunology, Immunotherapy : CII·Mette ThornMogens H Claesson
Feb 16, 2005·Springer Seminars in Immunopathology·Maurizio ZanettiPierre Langlade-Demoyen
Nov 13, 2008·Cytotechnology·Kunal P Patel, Robert H Vonderheide
Aug 30, 2001·Trends in Immunology·J L Schultze, R H Vonderheide
Aug 27, 2005·Leukemia·A Van DriesscheV F I Van Tendeloo
Sep 24, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M YasukawaH Fujiwara
Oct 27, 2011·Clinical & Developmental Immunology·Norimitsu Kadowaki, Toshio Kitawaki
Feb 3, 2004·The Journal of Clinical Investigation·David-Alexandre GrossKostas Kosmatopoulos
Jan 29, 2005·Journal of Translational Medicine·Yasuto AkiyamaKen Yamaguchi
Feb 28, 2007·Journal of Translational Medicine·Xochtil Cortez-Gonzalez, Maurizio Zanetti
Jan 1, 2009·Immunotherapy·Anna-Katharina Thomas-Kaskel, Hendrik Veelken
May 15, 2010·Future Oncology·Michelle F MaritzKaren L MacKenzie
Feb 14, 2002·Nucleic Acids Research·Jean-Louis MergnyEric Gilson
Oct 18, 2007·Urologia Internationalis·Elisabeth SieversAngela Marten
Jun 26, 2007·Journal of Immunotherapy·Masahiro KawaharaTakashi Uchiyama
Feb 17, 2011·Expert Review of Hematology·Gheath Alatrash, Jeffrey J Molldrem
Sep 26, 2007·Expert Review of Anticancer Therapy·Giuseppe CuriglianoAron Goldhirsch
Sep 23, 2006·Expert Opinion on Biological Therapy·Erica L Carpenter, Robert H Vonderheide
Dec 8, 2006·Expert Opinion on Biological Therapy·J Nemunaitis, J Nemunaitis
Sep 16, 2008·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Vaios KaranikasAnastasios E Germenis
Dec 7, 2007·European Urology·Andrea KiesslingMarc Schmitz
Apr 20, 2004·International Journal of Cancer. Journal International Du Cancer·Kouhei TajimaKiyotaka Kuzushima
May 16, 2009·Cancer Science·Yoshihiko HirohashiNoriyuki Sato
Feb 2, 2008·International Journal of Cancer. Journal International Du Cancer·Atsushi NatsumeJun Yoshida
Apr 18, 2007·Clinical and Experimental Immunology·A J Barrett, K Rezvani

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.